Trastuzumab Deruxtecan

Molecular Name: Trastuzumab Deruxtecan
Active Ingredient: Trastuzumab Deruxtecan
Strength:100mg/vial
Manufacturer Name: 

Metastatic breast cancer has spread to other parts of the body or cannot be surgically removed and is treated with Trastuzumab Deruxtecan in India.

Trastuzumab Deruxtecan marketed under the name Enhertu, is at affordable price in India and is for adult patients with metastatic or unresectable HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting or in the neoadjuvant or adjuvant settings and have developed the disease.


Trastuzumab Deruxtecan should be administered as a 5.4 mg/kg intravenous infusion once every three weeks (on a 21-day cycle) until the disease progresses or there is unacceptable toxicity. We assist with Trastuzumab Deruxtecan injection pricing, details, and uses, ARKON SOLUTIONS, through Name patient Import Services or Govt Hospital Supply.

Pharmaceutical Particulars

List of excipients

  • L-histidine
  • L-histidine hydrochloride monohydrate
  • Sucrose
  • Polysorbate 80

Special storage precautions

  • At temperatures between 2 and 8 °C, chemical and physical in-use stability has been proven to last up to 24 hours.
  • It is advised that the diluted solution be applied right away. If not used immediately, the reconstituted solution diluted in infusion bags containing 5% glucose solution may be stored for up to 4 hours at room temperature ( 30 °C) or for up to 24 hours in the refrigerator at 2 °C to 8 °C, away from light. These storage intervals begin at reconstitution.
  • Avoid freezing
Pharmaceutical Particulars

FAQ’s

If a patient meets the requirements, Trastuzumab Deruxtecan may be used to treat HER2-positive breast cancer, lung cancer, or stomach cancer. In individuals with metastatic breast cancer or breast cancer that could not be surgically removed, Trastuzumab Deruxtecan was effective at reducing the tumour, according to a current major trial. A minimum of two HER2-based therapies were administered to each patient. Additionally, HER2 is prevented from promoting the expansion of cancer cells by trastuzumab. Overexpression of HER2 is seen in about approximately 25% of breast cancers. When a patient has had two or more HER2-targeted therapies, Enhertu is administered independently.

Trastuzumab Deruxtecan needs to be ordered by a doctor. It should be administered under the direction of a medical expert with experience using cancer medications that have written a prescription. Once every three weeks, it is administered by infusion into a vein for over 90 minutes. Patients who tolerate the initial 90-minute infusion can get further infusions over 30 minutes. As long as the treatment plan is still working, it may be continued. The patient should be watched throughout and after the infusion for symptoms like fever and chills since the infusion may trigger allergic reactions. If the patient experiences side effects, the doctor may lower the dose or temporarily or permanently stop the medication.

The preservative is absent from Trastuzumab Deruxtecan. Reconstituted Trastuzumab Deruxtecan vials should be kept in the refrigerator for up to 24 hours after reconstitution at a temperature between 2 and 8 degrees Celsius, 36 and 46 degrees Fahrenheit, and away from light. You can try not to freeze. After 24 hours of refrigeration, discard any leftovers. Trastuzumab Deruxtecan should be administered intravenously once every three weeks on a 21-day cycle until the condition progresses or the side effects become intolerable. The suggested dose is 5.4 mg/kg. A 90-minute intravenous infusion of the first dose is recommended. Use only a polyolefin or polybutadiene infusion set and an in-line polyethersulfone (PES) or polysulfone (PS) filter with an intravenous infusion set while giving Trastuzumab Deruxtecan.

Trastuzumab Deruxtecan can only be applied when it has been established that cancer “overexpressed HER2″—that is, when it overproduces the protein HER2 on the surface of the tumor cells, causing the tumor cells to multiply more quickly. Patients who have had two or more HER2-targeted therapies are treated with Trastuzumab Deruxtecan alone.

The patient should be watched during and after the infusion for symptoms like fever and chills because the infusion may cause allergic reactions. If the patient experiences side effects, the doctor may lower the dose or temporarily or permanently stop the treatment.

  1. A physician should only administer Enhertu with knowledge of cancer drugs.
  2. Do not mix Trastuzumab Deruxtecan with other medicinal products or administer other medicinal products through the same intravenous line.
  3. Trastuzumab Deruxtecan is administered intravenously. It must be administered as an intravenous infusion after being reconstituted and diluted by a medical expert. Pushes or boluses into the vein should not be used to give Trastuzumab Deruxtecan.
  4. Look for particles and discoloration in the reconstituted solution. The mixture must be transparent and pale yellow to colorless. If there are visible particles, the solution is hazy, or it has a discolored appearance, do not use it.
  5. If not used right away, keep the reconstituted Trastuzumab Deruxtecan vials in the refrigerator, away from light, at a temperature between 2 and 8 degrees Celsius for up to 24 hours. Avoid freezing.
  6. Waste and unnecessary pharmaceuticals should be disposed of following local laws.
  1. When you have a nasty infection.
  2. If a patient is breastfeeding or is pregnant.
  3. If one has Hypersensitivity to any product ingredient.
  •  Nausea
  •  Low white blood cell counts
  •  Low red blood cell counts
  •  Increased liver function tests
  •  Feeling tired
  •  Vomiting
  •  Low platelet counts
  •  Hair loss
  •  Constipation
  •  Low levels of blood potassium
  •  Decreased appetite
  •  Diarrhea
  •  Pain in muscles and bones
  •  Infections of the respiratory tract
  •  Headache
  •  Stomach area (abdominal) pain

Four years